Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials

被引：0

作者：

Herbel, N. ^{[1
]}

Ouali, K. ^{[1
]}

Danlos, F-X. ^{[1
]}

Massard, C. P. ^{[1
]}

Goldschmidt, V. ^{[1
]}

Michot, J-M. ^{[1
]}

Laparra, A. ^{[2
]}

Bernard-Tessier, A. ^{[3
]}

Gazzah, A. ^{[1
]}

Bahleda, R. ^{[1
]}

Hollebecque, A. ^{[1
]}

Henon, C. ^{[1
]}

Postel-Vinay, S. ^{[1
]}

Loriot, Y. ^{[1
]}

Ribrag, V. ^{[1
]}

Marabelle, A. ^{[1
]}

Fizazi, K. ^{[3
]}

Aix, S. Ponce ^{[1
]}

Champiat, S. ^{[1
]}

Baldini, C. ^{[1
]}

机构：

[1] Inst Gustave Roussy, Drug Dev Dept, Villejuif, France

[2] Inst Gustave Roussy, DIOPP, Villejuif, France

[3] Gustave Roussy Canc Campus, Med Oncol Dept, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.723

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

657P

引用

页码：S519 / S519

页数：1

共 50 条

[1] T cell engager (TCE) score in patients treated with bispecific CD3 TCE in phase I clinical trials
Herbel, Noe
Goldschmidt, Vincent
Michot, Jean-Marie
Laparra, Ariane
Geraud, Arthur
Ouali, Kaissa
Danlos, Francois-Xavier
Vuagnat, Perrine
Bernard-Tessier, Alice
Gazzah, Anas
Bahleda, Rastilav
Hollebecque, Antoine
Marabelle, Aurelien
Postel-Vinay, Sophie
Loriot, Yohann
Massard, Christophe
Ribrag, Vincent
Aix, Santiago Ponce
Champiat, Stephane
Baldini, Capucine
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
Reed, Daniel R.
Lum, Lawrence G.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (08) : 761 - 772
[3] The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm
Suurs, Frans, V
Lorenczewski, Grit
Stienen, Sabine
Friedrich, Matthias
de Vries, Elisabeth G. E.
de Groot, Derk Jan A.
Lub-de Hooge, Marjolijn N.
JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (11) : 1594 - 1601
[4] PROSPECTIVE VALIDATION OF A PROGNOSTIC SCORE FOR PATIENTS TREATED IN PHASE-I TRIALS
Barriuso, J.
Arkenau, H. T.
Olmos, D.
Ang, J.
Brunetto, A.
Frentzas, S.
Ayite, B.
De-Bono, J.
Judson, I.
Kaye, S.
ANNALS OF ONCOLOGY, 2008, 19 : 164 - 164
[5] Bispecific T-Cell Engager Antibodies in Multiple Myeloma- a Systematic Review of Phase 1 Clinical Trials
Hashim, Laila
Faisal, Muhammad Salman
Iqbal, Muhammad Areeb
Saeed, Hassan
Samhouri, Yazan
Shahzad, Moazzam
Khattak, Zoia Ehsan
Anwer, Faiz
BLOOD, 2021, 138
[6] Preclinical validation of a novel CD133/CD3 bispecific T -cell engager (BiTE) antibody to target patient -derived glioblastoma cells
Vora, Parvez
Venugopal, Chitra
Adams, Jarrett
Pan, James
Chokshi, Chirayu
Qazi, Maleeha
Subapanditha, Minomi
Singh, Mohini
Bakhshinyan, David
Bezverbnaya, Ksenia
McFarlane, Nicole
Bramson, Jonathan
Sidhu, Sachdev
Moffat, Jason
Singh, Sheila
CANCER RESEARCH, 2016, 76
[7] Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma
Sangsuwannukul, Thanich
Supimon, Kamonlapat
Chieochansin, Thaweesak
Choomee, Kornkan
Sujjitjoon, Jatuporn
Junking, Mutita
Yenchitsomanus, Pa-Thai
PLOS ONE, 2022, 17 (03):
[8] Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Goebeler, Maria-Elisabeth
Bargou, Ralf
LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1021 - 1032
[9] FDA approves first DLL3 x CD3 bispecific T-cell engager for lung cancer
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (07) : 487 - 487
[10] Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo
G. de Jong
L. Bartels
M. Kedde
E. M. E. Verdegaal
M. A. Gillissen
S. E. Levie
M. G. Cercel
S. E. van Hal-van Veen
C. Fatmawati
D. van de Berg
E. Yasuda
Y. B. Claassen
A. Q. Bakker
S. H. van der Burg
R. Schotte
J. Villaudy
H. Spits
M. D. Hazenberg
P. M. van Helden
K. Wagner
Cancer Immunology, Immunotherapy, 2021, 70 : 1569 - 1581

← 1 2 3 4 5 →